Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report

The effectiveness of the tyrosine kinase inhibitor ALK (TKI) for non-small cell lung cancer has been confirmed. However, resistance to ALK-TKIs seems inevitable. Mutations in the ALK kinase domain have been reported as an important mechanism of acquired resistance to ALK therapy. However, patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jiuzhou, Li, Xiang, Fan, Ruizhe, Qin, Yaping, Wang, Zhizhong, Wang, Bo, Li, Shaomei, Fan, Jianfeng, Wu, Xinxin, Liu, Hongxia, Guan, Yuping, Liang, Yinfeng, Zhang, Xiao, Guo, Yongjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727108/
https://www.ncbi.nlm.nih.gov/pubmed/36506539
http://dx.doi.org/10.3389/fphar.2022.1060460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727108/
https://www.ncbi.nlm.nih.gov/pubmed/36506539
http://dx.doi.org/10.3389/fphar.2022.1060460

Ejemplares similares